Welcome to our dedicated page for Aprea Therapeutics news (Ticker: APRE), a resource for investors and traders seeking the latest updates and insights on Aprea Therapeutics stock.
Aprea Therapeutics, Inc. (APRE) is a clinical-stage biopharmaceutical leader developing precision oncology therapies through synthetic lethality approaches. This page provides investors and researchers with timely updates on the company’s progress in targeting DNA damage response pathways in solid tumors.
Access authoritative reporting on Aprea’s pipeline developments, including its ATRN-119 and APR-1051 programs. Our curated news collection covers clinical trial milestones, regulatory updates, and strategic collaborations, helping stakeholders track innovations in targeted cancer therapies.
Key content includes updates on phase 1/2 trial results, FDA communications, intellectual property expansions, and research partnerships. All content is verified through primary sources to ensure accuracy in this fast-evolving therapeutic area.
Bookmark this page for centralized access to Aprea’s latest scientific advancements and corporate announcements. Check regularly for developments in next-generation oncology treatments leveraging synthetic lethality mechanisms.
Aprea Therapeutics (Nasdaq: APRE) announced a partial clinical hold on its eprenetapopt trials in myeloid malignancies after a review by the FDA. About 20 patients are currently in the program, which includes MDS and AML, and can continue treatment. No new enrollments are permitted until the hold is resolved. Aprea aims to address FDA concerns and resume trials quickly. Ongoing trials in lymphoid malignancies and solid tumors remain unaffected. A webcast to discuss the situation will be held on August 6, 2021.
Aprea Therapeutics, Inc. (Nasdaq: APRE) announced positive results from a Phase 2 trial of eprenetapopt combined with azacitidine for post-transplant maintenance therapy in patients with TP53 mutant MDS and AML. The trial showed a 58% relapse-free survival and 79% overall survival at one year post-transplant. Previous trials reported much lower outcomes, indicating the potential impact of this therapy. The regimen was well tolerated, and discussions with the FDA are planned. Aprea has received multiple designations for its products aimed at treating hematologic malignancies.
Aprea Therapeutics (Nasdaq: APRE) announced promising results from its Phase 1/2 trial of eprenetapopt combined with venetoclax and azacitidine for treating TP53 mutant AML. The trial met its primary efficacy endpoint, achieving a 37% complete remission rate among 30 efficacy-evaluable patients, with a composite response rate of 53%. The findings will be discussed with the FDA in the latter half of 2021, and Aprea aims to present further data at upcoming conferences. The company continues to advance its myeloid malignancies program, leveraging the potential of eprenetapopt.
Aprea Therapeutics, Inc. (Nasdaq: APRE) announced on May 21, 2021, that Greg Korbel, Senior Vice President and Chief Business Officer, will present a corporate update at the 2021 Oppenheimer Rare & Orphan Disease Summit at 3:45 p.m. ET. A webcast can be accessed on the Aprea website. The company focuses on novel cancer therapeutics, primarily targeting the p53 tumor suppressor protein. Their lead candidate, eprenetapopt (APR-246), has received multiple FDA designations for conditions including myelodysplastic syndromes and acute myeloid leukemia. A next-generation candidate, APR-548, is also in development.
Aprea Therapeutics (Nasdaq: APRE) announced participation by CEO Christian S. Schade and CMO Eyal C. Attar in a fireside discussion at the 2021 RBC Capital Markets Global Healthcare Conference on May 18, 2021, at 2:30 p.m. ET. The conference will explore Aprea's focus on developing cancer therapeutics targeting mutant p53 protein. Their lead candidate, eprenetapopt (APR-246), has received multiple FDA designations for various cancers. A webcast of the event will be available on their website.
Aprea Therapeutics (Nasdaq: APRE) reports Q1 2021 financial results, revealing a net loss of $9.7 million or $0.46 per share. The company reported a decrease in R&D expenses to $6.8 million, down from $9.1 million a year earlier. Aprea continues development of eprenetapopt and APR-548 across several clinical trials. While a Phase 3 trial did not meet primary efficacy endpoints, interim analyses from other trials indicated promising rates of relapse-free survival and overall survival. The company expects its cash reserves will sustain operations into 2023.
Aprea Therapeutics, Inc. (Nasdaq: APRE) announced a virtual R&D Day on April 22, 2021, at 1:00 p.m. ET. This event will feature presentations by CEO Christian S. Schade and CMO Eyal C. Attar, focusing on the results of a completed Phase 3 trial for MDS and ongoing research. Register for the event on Aprea's website, where a replay will be available afterward. Aprea specializes in cancer therapies that reactivate the p53 protein, with its lead candidate, eprenetapopt (APR-246), showing promise in treating various cancers.
Aprea Therapeutics (Nasdaq: APRE) announced the FDA's Orphan Drug designation for eprenetapopt, aimed at treating acute myeloid leukemia (AML). This follows the prior Fast Track designation granted in November 2020. Orphan Drug designation offers several benefits, including a seven-year market exclusivity post-approval and FDA support in clinical trial design. Eprenetapopt is being developed to reactivate the mutant p53 protein in cancer cells, with additional designations for other conditions, including myelodysplastic syndromes and ovarian cancer.
Aprea Therapeutics (Nasdaq: APRE) reported financial results for 2020, highlighting a net loss of $15.4 million, or $0.73 per share. Their pivotal Phase 3 trial for eprenetapopt missed its primary endpoint for complete remission but showed a 53% improvement versus control. The Company has multiple ongoing trials for eprenetapopt and APR-548, their next-generation p53 reactivator, and expects to present additional findings in Q2 2021. As of December 31, 2020, cash and cash equivalents were $89 million, with anticipated cash burn of $30-35 million for 2021.
Aprea Therapeutics (Nasdaq: APRE), a biopharmaceutical company, is set to present a corporate update at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021, at 2:50 p.m. ET. The presentation will provide insights into the company's innovative cancer therapeutics aimed at reactivating the p53 tumor suppressor protein. A live webcast will be available on the company's website. Aprea's lead product candidate, eprenetapopt (APR-246), is in clinical development and has received various FDA designations for myelodysplastic syndromes and acute myeloid leukemia.
